A study to evaluate the efficacy and safety profile of inhaled corticosteroid/long acting beta agonist combination among COPD patients

DEPARTMENT OF PHARMACOLOGY0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patient age more than 40 years.
•2. At least 1 inpatient visit with a primary diagnosis for COPD (Spirometry: post bronchodilator- FEV1/FVC < 0.70).
•3. At least 1 ED visit with a COPD diagnosis (either primary or secondary).
•4. Patient not having an exacerbation for one month prior to study entry.
•5. Patient on inhalational therapy â?? 2-3 weeks.

•1. Patient diagnosed with asthma or other non-COPD respiratory disorder.
•2. Any previous lung volume reduction surgery AND/OR lung transplantation.
•3.A requirement for oxygen therapy for at least 12 hours per day.
•4. Any exclusionary co-morbid medical condition (cystic fibrosis, bronchiectasis, respiratory cancer, pulmonary fibrosis, pneumoconiosis, sarcoidosis, or any other condition likely to cause death within 3 years.
•5. Current use of oral/injectable corticosteroid therapy.
•6. Patients (diagnosed with cancer) who received >= 180 days of oral corticosteroids (OCS) in the 12-month pre-index period.
•7. Patients who initiated both study medications on the same date.
•8. Immuno-compromised (HIV +ve) patients

发起方